Escitalopram causes fewer seizures in human overdose than citalopram

Yilmaz, Zeynep; Ceschi, Alessandro; Rauber-Lüthy, Christine; Sauer, Oliver; Stedtler, Uwe; Prasa, Dagmar; Seidel, Carola; Hackl, Elisabeth; Hoffmann-Walbeck, Petra; Gerber-Zupan, Gabriela; Bauer, K. H.; Kupferschmidt, Hugo; Kullak-Ublick, Gerd-Achim; Wilks, Martin F.

doi:10.3109/15563650903585937

Cited by 30 publications

(25 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a multicenter retrospective review, escitalopram, the S-enantiomer of citalopram, was found to cause fewer seizures in overdose situations. 10 Metabolic acidosis has been reported in 4 cases of citalopram overdose including a case of seizures followed by metabolic acidosis in a 20-year-old woman after ingesting 1800 mg of citalopram in a suicide attempt. 11 Citalopram and escitalopram also have rarely been reported to cause QTc interval widening with therapeutic use and in overdose because of inhibition of sodium, potassium, and calcium channels.…”

Section: Citalopram/escitaloprammentioning

confidence: 98%

Recognizing Serotonin Toxicity in the Pediatric Emergency Department

Kant

Liebelt

2012

Pediatric Emergency Care

View full text Add to dashboard Cite

The use of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in treating depression, mood disorders, and behavioral disorders has escalated dramatically in the last 20 years, resulting in increased risk and clinical presentation of serotonin toxicity. Health care providers must also be aware of other medications and substances with proserotonergic activity that can cause serotonin toxicity when used in combination with these medications. There are many adverse effects of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, although their toxicity profile compared to older antidepressants seems to be safer. Serotonin syndrome is described as a clinical triad of mental status changes, autonomic hyperactivity, and neuromuscular abnormalities. It encompasses a spectrum of clinical findings ranging from a few nonspecific symptoms to significant clinical toxicity that can result in death. The objectives of this article are to review specific serotonergic medications including their adverse effects and toxicity in overdose, to describe other medications/substances that have proserotonergic effects, which could result in serotonin excess in combination with traditional serotonergic agents, and to define the criteria for serotonin syndrome/toxicity and its treatment.

show abstract

Section: Citalopram/escitaloprammentioning

confidence: 98%

Recognizing Serotonin Toxicity in the Pediatric Emergency Department

Kant

Liebelt

2012

Pediatric Emergency Care

View full text Add to dashboard Cite

show abstract

“…Эсциталопрам метаболизируется через CYP2C, благодаря чему не обладает ни индукционным, ни ингибиторным профилем по отношению к противоэ-пилептической терапии [36].…”

Section: больная к-ва 1985 года рожденияunclassified

Phenomenology and Therapy of Affective Disorders in Epilepsia

Усюкина¹

2018

Med. sov.

View full text Add to dashboard Cite

“…Both citalopram and escitalopram are capable of provoking generalized seizures 40,41. Citalopram and escitalopram are known to cause dose-dependent QT prolongation, although the mechanism remains uncertain and may be unrelated to serotonin reuptake per se 1,2.…”

Section: Pharmacological Mechanisms Responsible For Cardiovascular Efmentioning

confidence: 99%

Clinical use of antidepressant therapy and associated cardiovascular risk

Waring¹

2012

DHPS

View full text Add to dashboard Cite

A number of different psychotropic agents have been associated with an increased risk of cardiovascular disease, and these relationships have been difficult to interpret due to the presence of confounding factors. Recently, there has been renewed interest in the potential for certain antidepressants to cause QT prolongation, which is a predisposing factor for arrhythmia. However, the optimum means of determining QT remains contentious due to discrepancies between methods that may be readily applied in a clinical setting versus more detailed techniques during regulatory assessment. A number of different pharmacological mechanisms might explain the occurrence of adverse cardiac effects, and these differ according to the type of antidepressant agent. Emerging data indicate that citalopram exhibits a dose-effect relationship for QT prolongation. Whereas cardiotoxicity is readily apparent in the context of intentional antidepressant overdose, the occurrence of cardiac effects as a result of therapeutic administration is less certain. Pre-existing cardiac disease and other factors that independently predispose to arrhythmia are important considerations. Therefore, clinical judgment is needed to evaluate the overall risk or benefit of a particular antidepressant in any patient. Close monitoring should be considered for those at greatest risk of QT prolongation and arrhythmia.

show abstract

Escitalopram causes fewer seizures in human overdose than citalopram

Cited by 30 publications

References 24 publications

Recognizing Serotonin Toxicity in the Pediatric Emergency Department

Recognizing Serotonin Toxicity in the Pediatric Emergency Department

Phenomenology and Therapy of Affective Disorders in Epilepsia

Clinical use of antidepressant therapy and associated cardiovascular risk

Contact Info

Product

Resources

About